EA201491519A1 - Факторы свертывания крови пролонгированного действия и способы их получения - Google Patents

Факторы свертывания крови пролонгированного действия и способы их получения

Info

Publication number
EA201491519A1
EA201491519A1 EA201491519A EA201491519A EA201491519A1 EA 201491519 A1 EA201491519 A1 EA 201491519A1 EA 201491519 A EA201491519 A EA 201491519A EA 201491519 A EA201491519 A EA 201491519A EA 201491519 A1 EA201491519 A1 EA 201491519A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
reception
factors
blood collection
prolonged action
Prior art date
Application number
EA201491519A
Other languages
English (en)
Other versions
EA028578B1 (ru
Inventor
Уди Эйял Фима
Джили Харт
Original Assignee
Опко Байолоджикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48983616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201491519(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/372,540 external-priority patent/US8759292B2/en
Application filed by Опко Байолоджикс Лтд. filed Critical Опко Байолоджикс Лтд.
Publication of EA201491519A1 publication Critical patent/EA201491519A1/ru
Publication of EA028578B1 publication Critical patent/EA028578B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)

Abstract

Раскрыты полипептиды, включающие по меньшей мере один карбоксиконцевой пептид (СТР) хорионического гонадотропина, присоединенный к карбоксильному концу, но не к N-концу, фактора свертывания крови, и полинуклеотиды, кодирующие указанные полипептиды. Также раскрыты фармацевтические композиции, содержащие полипептиды и полинуклеотиды согласно настоящему изобретению, и способы их применения и получения.
EA201491519A 2012-02-14 2013-02-05 Факторы свертывания крови пролонгированного действия и способы их получения EA028578B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/372,540 US8759292B2 (en) 2006-02-03 2012-02-14 Long-acting coagulation factors and methods of producing same
US13/372,540 2012-02-14
PCT/IL2013/050107 WO2013121416A1 (en) 2012-02-14 2013-02-05 Long-acting coagulation factors and methods of producing same

Publications (2)

Publication Number Publication Date
EA201491519A1 true EA201491519A1 (ru) 2014-12-30
EA028578B1 EA028578B1 (ru) 2017-12-29

Family

ID=48983616

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201790960A EA201790960A3 (ru) 2012-02-14 2013-02-05 Факторы свертывания крови пролонгированного действия и способы их получения
EA201491519A EA028578B1 (ru) 2012-02-14 2013-02-05 Факторы свертывания крови пролонгированного действия и способы их получения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201790960A EA201790960A3 (ru) 2012-02-14 2013-02-05 Факторы свертывания крови пролонгированного действия и способы их получения

Country Status (22)

Country Link
EP (3) EP3791890A1 (ru)
JP (2) JP6242819B2 (ru)
KR (3) KR102310704B1 (ru)
CN (2) CN104427994A (ru)
AU (3) AU2013219935B2 (ru)
BR (1) BR122021004014B1 (ru)
CA (1) CA2870621C (ru)
CL (2) CL2014002183A1 (ru)
CO (1) CO7131365A2 (ru)
DK (2) DK3326642T3 (ru)
EA (2) EA201790960A3 (ru)
ES (2) ES2855133T3 (ru)
HK (1) HK1205460A1 (ru)
HU (1) HUE053068T2 (ru)
IL (2) IL264959B (ru)
MX (3) MX362446B (ru)
MY (1) MY172539A (ru)
NO (1) NO2920022T3 (ru)
PE (1) PE20142290A1 (ru)
PL (1) PL3326642T3 (ru)
SG (1) SG11201404836QA (ru)
WO (1) WO2013121416A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
MX362446B (es) 2012-02-14 2019-01-18 Opko Biologics Ltd Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
MX2017007635A (es) * 2014-12-10 2017-09-11 Opko Biologics Ltd Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada.
ES2893616T3 (es) * 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
US10745680B2 (en) 2015-08-03 2020-08-18 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
PT3481855T (pt) * 2016-07-11 2023-11-27 Opko Biologics Ltd Fator vii de coagulação de ação prolongada e métodos de produção do mesmo
WO2018032638A1 (zh) * 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
JP7023925B2 (ja) 2017-03-08 2022-02-22 テイ・エス テック株式会社 乗物用シート
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
EP0264166B1 (en) 1986-04-09 1996-08-21 Genzyme Corporation Transgenic animals secreting desired proteins into milk
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
DE69029799T2 (de) 1989-02-21 1997-05-28 Univ Washington Modifizierte formen von fortpflanzungshormonen
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
CN1245510C (zh) * 2003-09-25 2006-03-15 复旦大学 长效重组组织因子途径抑制物及其制备方法
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CA2733200A1 (en) * 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
MX362446B (es) 2012-02-14 2019-01-18 Opko Biologics Ltd Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.
MX363326B (es) * 2012-11-20 2019-03-20 Opko Biologics Ltd Metodo para incrementar el volumen hidrodinamico de polipeptidos mediante la union a peptidos carboxi-terminales de gonadotrofina.

Also Published As

Publication number Publication date
IL282121B (en) 2022-06-01
JP2018065815A (ja) 2018-04-26
HUE053068T2 (hu) 2021-06-28
MX2022008807A (es) 2022-08-11
DK2822576T3 (en) 2018-04-16
EA201790960A2 (ru) 2017-09-29
AU2016202829B2 (en) 2017-05-25
KR102118729B1 (ko) 2020-06-05
AU2017219044B2 (en) 2019-05-30
AU2013219935A1 (en) 2014-09-25
JP6242819B2 (ja) 2017-12-06
ES2665319T3 (es) 2018-04-25
MY172539A (en) 2019-11-30
CL2014002183A1 (es) 2015-01-09
MX2019000708A (es) 2020-09-02
JP6510002B2 (ja) 2019-05-08
MX362446B (es) 2019-01-18
ES2855133T3 (es) 2021-09-23
BR112014020198A2 (pt) 2018-05-15
WO2013121416A1 (en) 2013-08-22
EP2822576A4 (en) 2015-11-25
CA2870621C (en) 2022-08-09
MX2014009910A (es) 2015-09-28
EP2822576A1 (en) 2015-01-14
KR20210125595A (ko) 2021-10-18
KR102630953B1 (ko) 2024-01-29
PL3326642T3 (pl) 2021-06-14
IL282121A (en) 2021-05-31
EP3326642B1 (en) 2020-11-25
AU2013219935B2 (en) 2016-02-04
KR102310704B1 (ko) 2021-10-08
HK1205460A1 (en) 2015-12-18
BR122021004014B1 (pt) 2022-12-27
EP3791890A1 (en) 2021-03-17
EA201790960A3 (ru) 2018-01-31
CA2870621A1 (en) 2013-08-22
JP2015508771A (ja) 2015-03-23
CL2017002233A1 (es) 2018-05-11
EA028578B1 (ru) 2017-12-29
PE20142290A1 (es) 2015-01-15
KR20200063274A (ko) 2020-06-04
NO2920022T3 (ru) 2018-06-09
CN109535245A (zh) 2019-03-29
EP2822576B1 (en) 2018-01-10
AU2017219044A1 (en) 2017-09-14
CO7131365A2 (es) 2014-12-01
EP3326642A1 (en) 2018-05-30
IL264959B (en) 2021-08-31
CN104427994A (zh) 2015-03-18
AU2016202829A1 (en) 2016-05-19
KR20140134673A (ko) 2014-11-24
SG11201404836QA (en) 2014-12-30
DK3326642T3 (da) 2021-02-22

Similar Documents

Publication Publication Date Title
EA201491519A1 (ru) Факторы свертывания крови пролонгированного действия и способы их получения
TW201613958A (en) MIC-1 fusion proteins and uses thereof
EA201290254A1 (ru) Антагонисты il-17a
EA201491898A1 (ru) Варианты оксинтомодулина пролонгированного действия и способы получения указанных вариантов
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
CL2014003031A1 (es) Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras.
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
CL2014001779A1 (es) Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
CL2015003655A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
MY187047A (en) Selective pyy compounds and uses thereof
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins
WO2013036778A3 (en) Compstatin analogs with improved pharmacokinetic properties
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
MX2021012106A (es) Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015063465A3 (en) Novel polypeptides
WO2016203482A3 (en) Long-acting coagulation factors and methods of producing same
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
CL2014003185A1 (es) Preformulacion de baja viscosidad que comprende pasireotida, agonista del receptor de somatostatina; proceso de preparacion de la preformulacion; kit farmaceutico; uso para tratar enfermedad de cushing o acromegalia.
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
WO2015043566A8 (de) Zyklische, amyloid-beta-bindende peptide und deren verwendung
WO2014193800A3 (en) Aptamers for the treatment of sickle cell disease
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии